Who Owns Eurobio Scientific Company?

Who Owns Eurobio Scientific?

Understanding a company's ownership is key to grasping its direction and accountability. A significant development in 2024 was the tender offer by EB Development, a group including NextStage AM and IK Partners, aiming to increase their control over Eurobio Scientific.

This move highlights the evolving control structure of this life sciences company. Eurobio Scientific, established in 1997 and headquartered in Les Ulis, France, focuses on in vitro diagnostics and life science products.

As of July 2025, Eurobio Scientific is listed on Euronext Growth Paris (ALERS) with a market cap around $300 million. The company's revenue reached $167 million by the end of 2024. Their product offerings include diagnostic tests for various applications, such as infectious diseases and oncology, alongside the distribution of reagents and instruments. One notable product is the Eurobio Scientific BCG Matrix.

Eurobio Scientific was established in 1997, and its ownership journey has seen significant shifts. While the initial founder equity distribution isn't widely detailed, key figures have shaped its current structure, particularly Denis Fortier, the current Chairman and CEO.

Founding and Early Vision

Founded in 1997, the company's early vision was to become a prominent player in specialty in vitro diagnostics. This involved a strategic focus on developing proprietary products and expanding its international presence.

Key Acquisition in 2010

A pivotal moment in the company's ownership history occurred in 2010 when Denis Fortier and Jean-Michel Carle Grandmougin acquired the Eurobio laboratories. This acquisition marked a significant step in their involvement with the company.

Denis Fortier's Role

Denis Fortier, with over 30 years of experience in in vitro diagnostics and biotechnology, has been instrumental in the company's leadership. He assumed the roles of Chairman and CEO in June 2023.

Jean-Michel Carle Grandmougin's Involvement

Jean-Michel Carle Grandmougin also plays a crucial role as a Director and Deputy General Manager since June 2023. He also serves as the President of the EUROBIONEXT holding company.

Current Ownership Structure Insight

Denis Fortier holds a substantial stake, approximately 34%, in the EurobioNext holding company. This holding company, in turn, possesses around 30% of Eurobio Scientific's capital, indicating a significant ownership percentage.

Strategic Growth Objectives

The early leadership, including Fortier and Grandmougin, aimed to establish the company as a leader in specialty in vitro diagnostics. Their strategy included developing unique products and expanding into new international markets.

Eurobio Scientific Ownership Overview

Understanding who owns Eurobio Scientific involves looking at its key stakeholders and the company structure. The ownership is influenced by the strategic decisions made by its leadership and early investors.

• Eurobio Scientific was founded in 1997.
• Denis Fortier and Jean-Michel Carle Grandmougin acquired Eurobio laboratories in 2010.
• Denis Fortier is the current Chairman and CEO.
• Jean-Michel Carle Grandmougin is a Director and Deputy General Manager.
• Denis Fortier holds approximately 34% of EurobioNext, the parent holding company.
• EurobioNext holds about 30% of Eurobio Scientific's capital.
• The company's strategy has focused on proprietary product development and international expansion.
• Information on the full Eurobio Scientific stock ownership breakdown is often found in their investor relations disclosures.
• The Marketing Strategy of Eurobio Scientific is a key factor in its growth and market position.

Complete Eurobio Scientific Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Eurobio Scientific's ownership landscape has seen significant shifts, notably influenced by a voluntary public tender offer in 2024. This event consolidated a substantial portion of the company's capital under a key entity, reshaping its major stakeholder profile.

The evolution of Eurobio Scientific's ownership structure highlights a strategic move towards consolidation, aiming to bolster the company's financial capacity and development trajectory. This concentration of shares under EB Development, in collaboration with other significant investors and management, is designed to facilitate future growth, particularly through strategic acquisitions.

Key Stakeholders in Eurobio Scientific

Eurobio Scientific's ownership is primarily concentrated following a tender offer. Key entities and individuals are working together to drive the company's expansion.

• EB Development is the majority owner, holding a significant stake.
• NextStage AM, managing over €8.7 billion in assets as of September 30, 2024, is a key partner.
• IK Partners also plays an important role within the ownership consortium.
• Denis Fortier, the Chairman and CEO, is actively involved alongside senior management and the Board of Directors.
• The company is listed on Euronext Growth Paris, indicating public availability of some shares.

Eurobio Scientific, a company listed on Euronext Growth Paris (ALERS) since 2005, has experienced a notable shift in its ownership structure. The company's market capitalization stood at approximately $300 million USD on July 25, 2025, and €260.321 million on July 30, 2025. A pivotal moment in its ownership evolution was the voluntary public tender offer initiated in 2024, which led to EB Development acquiring a substantial stake. As of December 31, 2024, EB Development held 89.11% of the share capital and voting rights. This consolidation is a result of strategic alignment with funds managed by NextStage AM and IK Partners, as well as the company's Chairman and CEO, Denis Fortier, and other members of the Board of Directors and senior management. NextStage AM's involvement began on May 18, 2022, through a joint holding company, 'EurobioNext.' The influence of institutional investors like NextStage AM, which had over €8.7 billion in assets under management and advised as of September 30, 2024, is a significant factor. IK Partners also contributes to this ownership consortium. By November 29, 2024, approximately 44.7% of Eurobio Scientific's capital and voting rights were tendered in response to EB Development's initial offer, bringing their total stake to nearly 82.7% when considering shares held by NextStage AM, IK Partners, and management. Further solidifying this, by December 19, 2024, EB Development, in conjunction with these parties, held 9,113,592 shares, representing 88.92% of the share capital and voting rights. This concentrated ownership by EB Development, supported by NextStage AM and IK Partners, is intended to provide new financing avenues and accelerate Eurobio Scientific's development, particularly through external growth initiatives. Understanding the Mission, Vision & Core Values of Eurobio Scientific can provide context for these strategic ownership decisions.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Eurobio Scientific's governance is overseen by a Board of Directors, comprising between three and eighteen members, each serving a three-year term that can be renewed. The current leadership includes Denis Fortier as Chairman and CEO, supported by Directors and Deputy Executive Officers Jean-Michel Carle Grandmougin and Hervé Duchesne de Lamotte. Olivier Bosc serves as Deputy Managing Director and CFO, with Michel Picot holding the position of Vice-Chairman.

The voting power within Eurobio Scientific is highly concentrated, a situation significantly shaped by a recent tender offer. As of December 19, 2024, EB Development, in conjunction with funds managed by NextStage AM and IK Partners, alongside CEO Denis Fortier and other management members, collectively controlled 88.92% of the company's share capital and voting rights. This substantial ownership stake grants EB Development and its associated partners considerable influence over the company's strategic decisions. By May 19, 2025, EB Development further solidified its position, increasing its shareholding to 9,224,652 shares, which equates to 90.01% of Eurobio Scientific's share capital and voting rights. This achievement surpasses the threshold required for a potential squeeze-out procedure, indicating a strong alignment between the company's executive leadership and its primary institutional investors, a key aspect of the Target Market of Eurobio Scientific.

Key Ownership and Control Dynamics

The majority of Eurobio Scientific's voting power is held by a consortium led by EB Development.

• EB Development, NextStage AM, IK Partners, and management hold over 90% of voting rights.
• This concentration of Eurobio Scientific shareholders provides significant control.
• The current structure indicates a strong majority owner.
• Understanding this Eurobio Scientific ownership percentage is crucial for assessing corporate governance.

Eurobio Scientific Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Over the past few years, Eurobio Scientific has experienced significant changes in its ownership, largely due to a strategic tender offer that consolidated control. This shift reflects a broader industry movement towards private ownership for enhanced strategic flexibility.

The primary driver behind these ownership shifts is the voluntary tender offer launched in late 2024 by EB Development, a consortium including funds managed by NextStage AM and IK Partners, along with CEO Denis Fortier and other management members. This initiative aimed to increase private control, with EB Development's stake rapidly growing from 44.7% of tendered shares on November 29, 2024, to nearly 82.7% of the company's capital and voting rights. By December 19, 2024, this figure rose to 88.92%, and by May 19, 2025, it had surpassed the 90% threshold, indicating a potential squeeze-out procedure. The company cited that its public listing did not adequately support its development strategy, which relies heavily on external growth, and highlighted the challenging environment for mid-cap companies. The new ownership structure is intended to accelerate development with active shareholders who align with the company's vision in in vitro diagnostics and intelligent health. This strategic direction is supported by recent acquisitions, including the Life Science Unit of Voden Medical Instruments on March 11, 2025, and the EndoPredict® and Prolaris® oncology businesses in August 2024. The company anticipates that proprietary products will constitute approximately 50% of its revenues within the next five years.

Consolidated Ownership

EB Development's stake in Eurobio Scientific reached 90.01% by May 2025, signaling a significant shift towards private control.

Strategic Rationale

The move aims to provide greater flexibility for long-term strategic initiatives and reduce regulatory burdens, as the company seeks to finance its growth through external operations.

Acquisition Strategy

Recent acquisitions, including the Life Science Unit of Voden Medical Instruments and oncology businesses, support the goal of proprietary products contributing 50% of revenues in five years.

Industry Trends

The consolidation of Eurobio Scientific's ownership aligns with a broader industry trend where companies are delisting to gain agility and focus on strategic development, a topic also explored in the Competitors Landscape of Eurobio Scientific.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE